Peptide · Fact sheet
Trofinetide
Also known as Daybue · NNZ-2566
Trofinetide is FDA approved as Daybue for Rett syndrome in adults and children 2 years and older. It is not approved as a general cognitive, developmental, neuroprotective, or anti-aging peptide.
What is Trofinetide?
Trofinetide is a synthetic analog of glycine-proline-glutamate, a three-amino-acid fragment related to insulin-like growth factor 1 biology.
The approved claim rests on changes in caregiver- and clinician-rated Rett syndrome measures, not a cure or reversal of the condition.
Benefits people look for
Rett syndrome is a rare neurodevelopmental disorder with major communication, movement, and daily-function effects.
Its approval shows that a very small peptide analog can become a condition-specific neurology medicine, but does not validate broader brain-enhancement claims.
What the evidence supports
- The pivotal trial found better average change than placebo on a caregiver-rated Rett symptom score and a clinician global-impression measure.
- The trial did not establish a cure, disease reversal, or benefit outside Rett syndrome.
All research areas
- Rett syndrome symptoms
- Communication and behavior
- Neurodevelopmental function
- Longer-term Rett syndrome outcomes and functional effects
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Diarrhea and vomiting are prominent labeled adverse reactions and can be severe.
- The label warns about weight loss and the need for clinical monitoring.
- Long-term real-world effectiveness and tolerability may differ from the pivotal trial.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesA randomized Phase 3 trial supported statistically significant but modest changes on Rett-specific symptom scales. Evidence is condition-specific and does not establish restoration of lost function or benefit in other neurologic disorders.
Selected research to read
Pivotal controlled study of Rett-specific symptom and global-impression outcomes.
FDA approval & research status
FDA-approved Daybue labeling covers treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
Approved uses covered here
- Treatment of Rett syndrome in adults and pediatric patients 2 years of age and older under the Daybue label
FDA approved for Rett syndrome
Trofinetide is approved under the Daybue label for Rett syndrome in specified ages. The approval should not be generalized to other neurodevelopmental or cognitive claims.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Durability of functional benefit over many years
- Which individual characteristics predict meaningful response
- Effects on outcomes not captured well by the pivotal rating scales
- Whether related peptide analogs could help other neurodevelopmental disorders
The takeaway
Trofinetide is a genuine rare-neurology peptide medicine, not a broad cognitive enhancer. The average trial benefit was modest and gastrointestinal tolerability is central to its benefit-risk picture.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Daybue
Current approved indication, warnings, adverse reactions, and pivotal-study summary.
- 2pubmedLAVENDER randomized Phase 3 trial
Pivotal controlled study of Rett-specific symptom and global-impression outcomes.
- 3fdaFDA multidisciplinary review: Daybue
FDA review of efficacy, safety, trial interpretation, and approval considerations.